Table 1 Patients clinical characteristics.
Total (n = 500) | Evolocumab + Statin (n = 250 ) | Statins (n = 250) | P value | |
|---|---|---|---|---|
Age (years) | 61 (53,67) | 60 (51,67) | 62 (55,68) | 0.058 |
Male (n, %) | 410 (82.00) | 198 (79.20) | 212 (84.80) | 0.103 |
BMI (kg/㎡) | 25.39 (23.36,27.42) | 25.71 (23.45,27.55) | 25.35 (22.88,27.02) | 0.228 |
Smoke (n, %) | 245 (49.5) | 121 (48.80) | 124 (50.2) | 0.753 |
Alcohol(n, %) | 145 (29.30) | 79 (31.90) | 66 (26.70) | 0.209 |
Medical history (n, %) | ||||
Previous MI | 46 (9.20) | 23 (9.20) | 23 (9.20) | 1.000 |
Previous PCI | 53 (10.6) | 28 (11.2) | 25 (10.00) | 0.771 |
Previous CABG | 11 (2.20) | 8 (3.20) | 3 (1.20) | 0.221 |
Family history of CAD | 4 (0.80) | 2 (0.40) | 2 (0.40) | 1.000 |
Diabetes | 107 (21.4) | 58 (23.20) | 49 (19.60) | 0.326 |
Hypertension | 281 (56.20) | 138 (55.20) | 143 (57.20) | 0.652 |
Stroke | 42 (8.40) | 18 (7.20) | 24 (9.60) | 0.333 |
PUD | 14 (2.80) | 9 (3.60) | 5 (2.00) | 0.874 |
PAD | 7 (1.40) | 3 (1.20) | 4 (1.60) | 0.874 |
Type of ACS (n, %) | 0.149 | |||
STEMI | 398 (79.60) | 192 (76.80) | 206 (82.40) | |
NSTE-ACS | 102 (20.40) | 58 (23.20) | 44 (17.60) | |
Number of coronary artery lesion (n, %) | 0.379 | |||
Single-vessel lesion | 151 (30.60) | 80 (32.50) | 71 (28.70) | |
Double-vessel lesion | 148 (30.00) | 67 (27.20) | 81 (32.80) | |
Three-vessel lesion | 194 (39.40) | 99 (40.20) | 95 (38.50) | |
Coronary diseased vessels (n,%) | 0.710 | |||
LAD | 242 (49.10) | 127 (51.60) | 115 (46.60) | |
LCX | 65 (13.20) | 30 (12.20) | 35 (14.20) | |
RCA | 175 (35.50) | 84 (34.10) | 91 (36.80) | |
LM | 11 (2.20) | 5 (2.00) | 6 (2.40) | |
Clinical laboratory tests and examinations | ||||
WBC (x109/L) | 9.39 (7.67,11.31) | 9.11 (7.34,11.34) | 9.69 (8.08,11.26) | 0.077 |
Neutrophil percentage (%) | 73.35 (66.23,80.30) | 72.00 (64.70,80.30) | 74.70 (68.85,80.30) | 0.056 |
hs-CRP (mg/L) | 4.15 (1.60,8.54) | 4.01 (1.66,8.11) | 4.45 (1.57,9.01) | 0.393 |
PLT (x109/L) | 214.00 (179.00,254.00) | 215.00 (181.00,265.50) | 209.00(177.75,247.25) | 0.098 |
TC (mmol/L) | 4.77(4.23,5.20) | 4.87(4.37,5.21) | 4.65(4.21,5.19) | 0.206 |
TG (mmol/L) | 1.89(1.56,2.08) | 1.63(1.23,2.12) | 1.50(1.14,2.04) | 0.091 |
HDL-C (mmol/L) | 1.05(1.03,1.07) | 1.00(0.88,1.19) | 1.05(1.02,1.08) | 0.820 |
LDL-C (mmol/L) | 3.38(2.95,3.80) | 3.45(3.11,3.79) | 3.33(2.94,3.73) | 0.263 |
VLDL-C (mmol/L) | 0.41(0.27,0.59) | 0.43(0.29,0.62) | 0.39(0.24,0.56) | 0.136 |
UA (umol/L) | 325.00(273.00,393.00) | 319.50 (277.75,388.00) | 328.50 (269.00, 400.75) | 0.179 |
Cr (umol/L) | 77.00 (66.00,88.00) | 75.00 (64.75,85.25) | 79.00 (69.00,89.75) | 0.065 |
eGFR | 93.40 (81.78,105.06) | 95.01 (84.33,106.57) | 90.54 (78.37,103.86) | 0.064 |
FBG (mmol/L) | 6.24 (5.46,7.72) | 6.22 (5.35,8.18) | 6.31 (5.45,7.62) | 0.613 |
Hb1Ac (%) | 5.90 (5.60,6.60) | 5.90 (5.55,6.63) | 5.90 (5.60,6.60) | 0.549 |
D-dimer (ug/ml) | 0.34 (0.23,0.59) | 0.33 (0.23,0.57) | 0.36 (0.24,0.63) | 0.149 |
CK (U/L) | 1104.50 (366.75,2334.00) | 848.00(224.00,2639.50) | 1232.00(555.25,2137.50) | 0.062 |
CK-MB (U/L) | 101.00 (42.00,203.00) | 89.00 (25.50,223.00) | 112.50 (56.00,183.00) | 0.100 |
TNT (ng/mL) | 2.76 (0.74,6.48) | 2.14 (0.50,6.44) | 3.05 (0.93,6.50) | 0.061 |
BNP (pg/mL) | 136.85 (54.92,334.92) | 122.56 (49.70,305.43) | 158.94 (64.14,366.77) | 0.172 |
LVEF (%) | 50.50 (45.00,56.00) | 51.00 (45.00,57.00) | 50.00 (45.00,55.00) | 0.130 |
Other cardiac medications (n, %) | ||||
Aspirin | 500 (100) | 250 (100) | 250 (100) | 1.000 |
P2Y12inhibitor | 500 (100) | 250 (100) | 250 (100) | 1.000 |
ACEI/ARB | 368 (73.60) | 178 (71.20) | 190 (76.00) | 0.222 |
β-Blocke | 374 (74.80) | 184 (73.60) | 190 (76.00) | 0.537 |
Statins | 18(3.60) | 10(4.00) | 8(3.20) | 0.811 |
